Bank of New York Mellon
TRDA icon

Bank of New York Mellon’s Entrada Therapeutics TRDA Stock Holding History

Bank of New York Mellon’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Buy
79,070
+2,643
+3% +$25.3K ﹤0.01% 3673
2026
Q1 		$965K Sell
76,427
-2,948
-4% -$33.8K ﹤0.01% 3230
2025
Q4 		$816K Sell
79,375
-26,431
-25% -$223K ﹤0.01% 3349
2025
Q3 		$614K Buy
105,806
+7,778
+8% +$45.5K ﹤0.01% 3482
2025
Q2 		$659K Sell
98,028
-2,032
-2% -$16.3K ﹤0.01% 3359
2025
Q1 		$905K Sell
100,060
-1,298
-1% -$16.2K ﹤0.01% 3127
2024
Q4 		$1.75M Sell
101,358
-3,609
-3% -$65.4K ﹤0.01% 2818
2024
Q3 		$1.68M Sell
104,967
-20,469
-16% -$323K ﹤0.01% 2844
2024
Q2 		$1.79M Buy
125,436
+14,838
+13% +$211K ﹤0.01% 2855
2024
Q1 		$1.57M Sell
110,598
-4,462
-4% -$63.1K ﹤0.01% 2903
2023
Q4 		$1.74M Buy
115,060
+48,107
+72% +$713K ﹤0.01% 2903
2023
Q3 		$1.06M Buy
66,953
+566
+0.9% +$8.91K ﹤0.01% 3117
2023
Q2 		$1.01M Buy
66,387
+53,948
+434% +$743K ﹤0.01% 3192
2023
Q1 		$180K Hold
12,439
– – ﹤0.01% 3950
2022
Q4 		$168K Buy
+12,439
New +$218K ﹤0.01% 4019
2022
Q2 		– Sell
-21,933
Closed -$206K – 4699
2022
Q1 		$206K Buy
21,933
+8,276
+61% +$88.7K ﹤0.01% 4223
2021
Q4 		$234K Buy
+13,657
New +$331K ﹤0.01% 4210

Other funds holding TRDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's TRDA Position: Q2 2026 in Review

Bank of New York Mellon increased its Entrada Therapeutics (TRDA) stake by 3.5% in Q2 2026, buying an estimated $25.3K and bringing the position to 79,070 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #3673.

Bank of New York Mellon first reported a position in TRDA in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.79M in Q2 2024. 38 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Bank of New York Mellon held 79,070 shares of Entrada Therapeutics worth $582K as of Q2 2026.
  • Bank of New York Mellon bought 2,643 Entrada Therapeutics shares in Q2 2026, an estimated $25.3K.
  • Entrada Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3673 holding.
  • Bank of New York Mellon first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Bank of New York Mellon's Entrada Therapeutics position peaked at $1.79M in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.